Our findings suggest that TB culture can be implemented with reasonable cost-effectiveness in urban, middle-income Latin America.
In conclusion, this study suggests that TB culture for HIV-positive patients in urban Brazil may have substantial impact and reasonable cost-effectiveness.
Furthermore, the combination of the methods reported in this work and other ECG and physiological parameters is expected to lead to a solution for the prognosis of cardiovascular mortality at reasonable cost-effectiveness.
This operational evaluation of a centralized TB culture program serving HIV-positive patients in urban Brazil suggests that TB culture has substantial impact and reasonable cost-effectiveness when deployed in this setting.
In their recent publication, the NLST reports reasonable cost-effectiveness of LDCT screening of lung cancer [ 68].
In general, the results of this study showed atomoxetine to be within the bounds of reasonable cost-effectiveness for Spain.
A recently published economic analysis of diverse cardiologic interventions from 2000 to 2010 in England and Wales showed reasonable cost-effectiveness for ACE inhibitors, ranging from approximately 2500 Euros up to 4400 Euros for secondary prevention in heart failure patients.
The project was intended to evidence that a substantial reduction in Type 2 diabetes incidence can be obtained at a reasonable cost-effectiveness ratio in real-life primary health care setting by an intensive lifestyle intervention.
In the base case, compared to an ED discharge strategy, hospitalization had a very high marginal cost-effectiveness ratio of $684,101 per quality-adjusted life year, whereas observation unit admission exhibited a reasonable cost-effectiveness ratio of $44,249 per quality-adjusted life year [ 34].
The results of the analysis suggest that the clinical benefits of bortezomib, in terms of response, delay in disease progression, and improved OS, could be derived at a reasonable cost [incremental cost-effectiveness ratio (ICER) $US45 356 per life-year gained], relative to thalidomide and BSC, in patients with relapsed refractory multiple myeloma.
These estimates translate into a reasonable range of cost effectiveness in low and middle income countries; comparable to other proven public health strategies (See Figure 2).
